In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Context Therapeutics (CNTX – Research Report), with a price target of $6.00. The company’s shares opened today at $1.19.
Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Context Therapeutics, and Dice Therapeutics. According to TipRanks, Bodnar has an average return of -19.2% and a 21.21% success rate on recommended stocks.
Context Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $10.87 and a one-year low of $1.10. Currently, Context Therapeutics has an average volume of 352.5K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
- Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
- Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
- Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
